real-time news and commentary for investors
Saturday, Oct 5
Novartis, Genentech's omalizumab again proves effective in CSU
- Novartis (NVS) and Genentech's (RHHBY.OB) persistent allergic asthma treatment omalizumab performs well in ASTERIA I, the last of three Phase 3 registration studies (ASTERIA II and GLACIAL) for the treatment of chronic spontaneous urticaria, a form of hives for which antihistamines are one of the only available treatments.
- Patients responded as early as week one compared to week four for placebo and by the twelfth week, all three doses of omalizumab were "significantly superior to placebo in improving patients' weekly Itch Severity Score," the primary endpoint.
- ASTERIA I also "met all pre-specified secondary efficacy endpoints" except one. (PR)